Supramolecular chemistry enables vat photopolymerization 3D printing of novel water-soluble tablets.
3D printed drug products and printlets
Biocompatibility and safety of 3D printed devices
Clinical translation of printed medicines
Personalized pharmaceuticals
Printing formulations and drug delivery systems
Vat photopolymerization additive manufacturing
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Aug 2023
25 Aug 2023
Historique:
received:
19
06
2023
revised:
25
07
2023
accepted:
30
07
2023
medline:
21
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Vat photopolymerization has garnered interest from pharmaceutical researchers for the fabrication of personalised medicines, especially for drugs that require high precision dosing or are heat labile. However, the 3D printed structures created thus far have been insoluble, limiting printable dosage forms to sustained-release systems or drug-eluting medical devices which do not require dissolution of the printed matrix. Resins that produce water-soluble structures will enable more versatile drug release profiles and expand potential applications. To achieve this, instead of employing cross-linking chemistry to fabricate matrices, supramolecular chemistry may be used to impart dynamic interaction between polymer chains. In this study, water-soluble drug-loaded printlets (3D printed tablets) are fabricated via digital light processing (DLP) 3DP for the first time. Six formulations with varying ratios of an electrolyte acrylate monomer, [2-(acryloyloxy)ethyl]trimethylammonium chloride (TMAEA), and a co-monomer, 1-vinyl-2-pyrrolidone (NVP), were prepared to produce paracetamol-loaded printlets.
Identifiants
pubmed: 37532009
pii: S0378-5173(23)00706-8
doi: 10.1016/j.ijpharm.2023.123286
pii:
doi:
Substances chimiques
Acetaminophen
362O9ITL9D
Polymers
0
Tablets
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123286Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alvaro Goyanes reports a relationship with FabRx that includes: equity or stocks. Abdul Basit reports a relationship with FabRx that includes: equity or stocks. A.W.B. Co-author is an editor for International Journal of Pharmaceutics.